Demographic characteristics of the patients harboring a T315I mutation (n = 222)
| Characteristic . | Value . |
|---|---|
| Median age, y (range) | |
| At diagnosis | 49 (16-80) |
| At first time of TKI resistance | 52 (18-81) |
| At first time of T315I mutation detection | 54 (18-84) |
| CP (n = 82) | 60 (21-84) |
| AP (n = 38) | 51 (19-76) |
| BP (n = 56)* | 41 (21-79) |
| Ph+ ALL (n = 46)† | 52 (18-74) |
| Male/female, n (%) | 126/96 (56.8/43.2) |
| Race, n (%) | |
| White | 166 (74.5) |
| Asian | 49 (22.1) |
| Other | 7 (3.4) |
| Country/site, n (%) | |
| France | 72 (32.4) |
| Italy | 46 (20.7) |
| Korea, Republic of | 33 (14.9) |
| United States | 27 (12.2) |
| Germany | 17 (7.6) |
| Singapore | 13 (5.9) |
| Denmark | 6 (2.7) |
| United Kingdom | 5 (2.3) |
| Japan | 3 (1.4) |
| Disease phase at T315I detection, n (%) | |
| CML CP | 82 (36.9) |
| CML AP | 38 (17.1) |
| CML BP | 56 (25.2) |
| Ph+ ALL | 46 (20.7) |
| Characteristic . | Value . |
|---|---|
| Median age, y (range) | |
| At diagnosis | 49 (16-80) |
| At first time of TKI resistance | 52 (18-81) |
| At first time of T315I mutation detection | 54 (18-84) |
| CP (n = 82) | 60 (21-84) |
| AP (n = 38) | 51 (19-76) |
| BP (n = 56)* | 41 (21-79) |
| Ph+ ALL (n = 46)† | 52 (18-74) |
| Male/female, n (%) | 126/96 (56.8/43.2) |
| Race, n (%) | |
| White | 166 (74.5) |
| Asian | 49 (22.1) |
| Other | 7 (3.4) |
| Country/site, n (%) | |
| France | 72 (32.4) |
| Italy | 46 (20.7) |
| Korea, Republic of | 33 (14.9) |
| United States | 27 (12.2) |
| Germany | 17 (7.6) |
| Singapore | 13 (5.9) |
| Denmark | 6 (2.7) |
| United Kingdom | 5 (2.3) |
| Japan | 3 (1.4) |
| Disease phase at T315I detection, n (%) | |
| CML CP | 82 (36.9) |
| CML AP | 38 (17.1) |
| CML BP | 56 (25.2) |
| Ph+ ALL | 46 (20.7) |
ALL indicates acute lymphoblastic leukemia; AP, accelerated phase; BP, blastic phase; CML, chronic myeloid leukemia; CP, chronic phase; and Ph, Philadelphia chromosome.
Among the 56 CML BP patients, 16 were lymphoid, 32 were myeloid, and 8 were biphenotypic or the immunophenotype was missing.
A total of 40 (87%) of the 46 Ph+ ALL patients were from France (n = 22) and Italy (n = 18).